11/14
01:35 pm
virx
Viracta Therapeutics, Inc. (NASDAQ: VIRX) had its price target lowered by analysts at Royal Bank of Canada from $4.00 to $2.00. They now have an "outperform" rating on the stock.
Medium
Report
Viracta Therapeutics, Inc. (NASDAQ: VIRX) had its price target lowered by analysts at Royal Bank of Canada from $4.00 to $2.00. They now have an "outperform" rating on the stock.
11/13
07:00 am
virx
Viracta Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
High
Report
Viracta Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
11/6
04:43 pm
virx
Viracta Therapeutics Announces Reprioritization of Resources to Enhance Focus on Nana-val Development Program in Patients with Relapsed or Refractory EBV-Positive Peripheral T-Cell Lymphoma [Yahoo! Finance]
High
Report
Viracta Therapeutics Announces Reprioritization of Resources to Enhance Focus on Nana-val Development Program in Patients with Relapsed or Refractory EBV-Positive Peripheral T-Cell Lymphoma [Yahoo! Finance]
11/6
04:30 pm
virx
Viracta Therapeutics Announces Reprioritization of Resources to Enhance Focus on Nana-val Development Program in Patients with Relapsed or Refractory EBV-Positive Peripheral T-Cell Lymphoma
Medium
Report
Viracta Therapeutics Announces Reprioritization of Resources to Enhance Focus on Nana-val Development Program in Patients with Relapsed or Refractory EBV-Positive Peripheral T-Cell Lymphoma
10/22
09:59 am
virx
Post-Transplant Lymphoproliferative Disorder Drug Pipeline Market Research 2024: Therapeutics Assessment by Product Type, Stage, Route of Administration, and Molecule Type [Yahoo! Finance]
Low
Report
Post-Transplant Lymphoproliferative Disorder Drug Pipeline Market Research 2024: Therapeutics Assessment by Product Type, Stage, Route of Administration, and Molecule Type [Yahoo! Finance]
9/3
07:00 am
virx
Viracta Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
High
Report
Viracta Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference